David’s extensive experience at Astra Zeneca includes having accountability for the isolation and optimisation of antibodies, proteins, and peptides for therapeutic development. He and his team delivered lead molecules for the Respiratory, Inflammatory, and Autoimmunity antibody projects. David was the Global Head of In Vivo Expressed Biologics at AZ focusing on exploring and advancing new technologies such as AAV, DNA, mRNA and exosome delivery of biologics. David spent nearly 10 years at Cambridge Antibody Technology, prior to it being acquired by Astra Zeneca, where he led antibody engineering to develop novel antibody-based drugs. David has over 40 scientific publications, and is an inventor on numerous patents. David earned his Ph.D. from the University of Cambridge.